By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PCI Biotech 

Hoffsveien 48

Oslo    N-0377  Norway
Phone: 47-23-254003 Fax: 47-23-254001



Company News
PCI Biotech And RXi Pharma (RXII) Extend Research Collaboration To The Field Of Immuno-Oncology 5/22/2017 9:35:05 AM
New Data Confirms Early Implantation of Impella 2.5 Prior to PCI Biotech Improves Survival in Shock Patients 11/11/2011 6:27:37 AM
Main Results of the Full Phase I/II Study of PCI Biotech's Amphinex(R) 6/27/2011 9:55:53 AM
PCI Biotech: Main Results of the Full Phase I/II study of Amphinex(R) 6/24/2011 9:36:34 AM
PCI Biotech Announces Last Patient Included in the Phase I/II Study of PC-A11 2/23/2011 7:49:12 AM
PCI Biotech Raises NOK90 Million in Rights Issue 6/10/2010 6:39:26 AM
PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex(R) Trial 3/16/2010 9:52:58 AM
PCI Biotech Reports Successful Completion of Second Dose Group in Pivotal Amphinex(R) Trial 1/19/2010 10:07:50 AM
PCI Biotech Commences Phase I/II Trials of Amphinex(R) Light-Mediated Therapy Aims to Overcome Both Tumour Cell Uptake Barriers and Toxicity Problems 8/24/2009 8:04:30 AM
PCI Biotech: Anti-Tumour Drug More Potent With Light-Directed Delivery 8/19/2009 7:55:35 AM